Top

Published in:

01-12-2019 | Case Report

Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response

Authors: Vineet Govinda Gupta, Ranga Rao Rangaraju, Rajat Saha, Peush Bajpai

Published in: Journal of Gastrointestinal Cancer | Issue 4/2019

Excerpt

Metastatic gastroesophageal adenocarcinomas (GEA) constitute a challenging treatment problem. Two-thirds of all patients will either present with or develop metastatic disease over the course of their therapy. Despite advances in treatment, the prognosis of metastatic GEA remains poor with a median survival of less than 1 year, except perhaps for HER2/neu-amplified patients who can achieve better outcomes with the integration of HER2-directed targeted therapy [1]. The standard systemic therapy for metastatic GEA comprises palliative-intent chemotherapy, with multiple active agents given in several sequential “lines” of therapy. The most active agents tend to be platinum agents, fluoropyrimidines, and taxanes. However, fitness for chemotherapy, response rates, and progression-free survival drops from one line to the next due to disease progression and side effects of previous treatment. …

Shah MA. Update on metastatic gastric and esophageal cancers. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:1760–9. https://doi.org/10.1200/JCO.2014.60.1799.CrossRef

Kim S-E, Shim K-N, Jung S-A, Yoo K, Lee JH. The clinicopathological significance of tissue levels of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in gastric cancer. Gut Liver. 2009;3:88–94. https://doi.org/10.5009/gnl.2009.3.2.88.CrossRefPubMedPubMedCentral

Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 1996;77:858–63.CrossRefPubMed

Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:3968–76. https://doi.org/10.1200/JCO.2011.36.2236.CrossRef

Shen L, Li J, Xu J, Pan H, Dai G, Qin S, et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer. 2015;18:168–76. https://doi.org/10.1007/s10120-014-0351-5.CrossRefPubMed

Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31–9. https://doi.org/10.1016/S0140-6736(13)61719-5.CrossRefPubMed

Wilke H, Muro K, Van Cutsem E, Oh S-C, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224–35. https://doi.org/10.1016/S1470-2045(14)70420-6.CrossRefPubMed

Saito S, Muneoka Y, Ishikawa T, Akazawa K. Cost-effectiveness of paclitaxel + ramucirumab combination therapy for advanced gastric cancer progressing after first-line chemotherapy in Japan. Clin Ther. 2017;39:2380–8. https://doi.org/10.1016/j.clinthera.2017.10.017.CrossRefPubMed

Chen L-T, Oh D-Y, Ryu M-H, Yeh K-H, Yeo W, Carlesi R, et al. Anti-angiogenic therapy in patients with advanced gastric and gastroesophageal junction cancer: a systematic review. Cancer Res Treat. 2017;49:851–68. https://doi.org/10.4143/crt.2016.176.CrossRefPubMedPubMedCentral

10.

Hamberg P, Verweij J, Sleijfer S. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist. 2010;15:539–47. https://doi.org/10.1634/theoncologist.2009-0274.CrossRefPubMedPubMedCentral

11.

Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32:1412–8. https://doi.org/10.1200/JCO.2013.50.8267.CrossRef

12.

Kim ST, Lee J, Lee SJ, Park SH, Jung S-H, Park YS, et al. Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. Oncotarget. 2016;7:24088–96. https://doi.org/10.18632/oncotarget.8175.CrossRefPubMedPubMedCentral

13.

Burris HA, Dowlati A, Moss RA, Infante JR, Jones SF, Spigel DR, et al. Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors. Mol Cancer Ther. 2012;11:1820–8. https://doi.org/10.1158/1535-7163.MCT-11-0997.CrossRefPubMed

14.

Ulahannan SV, Brahmer JR. Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Investig. 2011;29:325–37. https://doi.org/10.3109/07357907.2011.554476.CrossRef

15.

Tan AR, Dowlati A, Stein MN, Jones SF, Infante JR, Bendell J, et al. Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies. Br J Cancer. 2014;110:2647–54. https://doi.org/10.1038/bjc.2014.233.CrossRefPubMedPubMedCentral

16.

du Bois A, Floquet A, Kim J-W, Rau J, del Campo JM, Friedlander M, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32:3374–82. https://doi.org/10.1200/JCO.2014.55.7348.CrossRef

17.

Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16:928–36. https://doi.org/10.1016/S1470-2045(15)00086-8.CrossRefPubMedPubMedCentral

18.

Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–83. https://doi.org/10.1056/NEJMoa1104390.CrossRefPubMed

19.

Lopez-Chavez A, Young T, Fages S, Leon L, Schiller JH, Dowlati A, et al. Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis. J Thorac Oncol. 2012;7:1707–12. https://doi.org/10.1097/JTO.0b013e318265b500.CrossRefPubMed

20.

Yu P, Huang L, Cheng G, Yang L, Dai G, Ying J, et al. Treatment strategy and prognostic factors for Krukenberg tumors of gastric origin: report of a 10-year single-center experience from China. Oncotarget. 2017;8:82558–70. https://doi.org/10.18632/oncotarget.19759.CrossRefPubMedPubMedCentral

21.

Kim ST, Jang H-L, Lee SJ, Lee J, Choi Y-L, Kim K-M, et al. Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification. Mol Cancer Ther. 2014;13:2527–36. https://doi.org/10.1158/1535-7163.MCT-14-0255.CrossRefPubMed

Title: Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response
Authors: Vineet Govinda Gupta
Ranga Rao Rangaraju
Rajat Saha
Peush Bajpai
Publication date: 01-12-2019
Publisher: Springer US
Published in: Journal of Gastrointestinal Cancer / Issue 4/2019
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-018-0130-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2019

Impact of Prior Malignancy on Survival Outcomes of Stage IV Pancreatic Adenocarcinoma: SEER-Based Cohort

Unexpected Prolonged Survival After Extended and Emergent Resection of Pancreatic Metastases from Renal Cell Carcinoma

Anticancer Activity of Earthworm Powder (Lumbricus terrestris) Against MCF-7 and PC-3 Cancer Cell Lines

Radio-pathological Correlation of 18F-FDG PET in Characterizing Gallbladder Wall Thickening

Gallbladder Carcinosarcoma with Mirizzi Syndrome: a Rare Presentation

Esophageal Squamous Cell Carcinoma Metastatic to Umbilicus: a Case Report with Review of Literature

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials